Globus Medical (GMED)
(Delayed Data from NYSE)
$70.99 USD
-0.23 (-0.32%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $70.97 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
GMED 70.99 -0.23(-0.32%)
Will GMED be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GMED
Why Is Globus Medical (GMED) Down 0.2% Since Last Earnings Report?
Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?
GMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
Other News for GMED
Janus Henderson Small-Mid Cap Value Fund Q2 2024 Commentary
Janus Henderson Small Cap Value Fund Q2 2024 Commentary
Janus Henderson Mid Cap Value Managed Account Q2 2024 Commentary
Janus Henderson Mid Cap Value Fund Q2 2024 Commentary
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary